Long-term outcomes following arteriovenous fistula ligation in kidney transplant recipients

Table 2 Multivariable analysis of peri-transplant clinical variables associated with allograft outcomes in patients receiving hemodialysis via arteriovenous fistulae vs central venous catheter pre-transplant

	Univariate			Multivariate
	HR	95%CI	P value	HR	95%CI	P value
All-cause allograft survival
Age (years)	1.03	1.02-1.03	< 0.001	1.02	1.01-1.03	< 0.001
Black ethnicity	1.21	0.95-1.55	0.13
Female	0.82	0.65-1.02	0.08
Diabetes	1.66	1.35-2.03	< 0.001	1.46	1.18-1.81	< 0.001
Time at ESKD	1.04	1.01-1.07	0.003	1.03	1.00-1.06	0.04
Living donor transplant	0.76	0.60-0.97	0.025
Total HLA mismatch	1.08	1.00-1.16	0.04
Delayed graft function	1.91	1.55-2.36	< 0.001	1.68	1.36-2.08	< 0.001
CVC	0.91	0.75-1.12	0.37
Death with a functioning graft
Age (years)	1.07	1.05-1.08	< 0.001	1.06	1.05-1.08	< 0.001
Female	1.03	0.43-0.91	0.015	0.64	0.43-0.94	0.021
Diabetes	1.96	1.43-2.69	< 0.001	1.57	1.13-2.19	0.008
Time at ESKD	1.05	1.01-1.09	0.013
Living donor transplant	0.62	0.42-0.92	0.019
Delayed graft function	1.82	1.31-2.54	< 0.001
CVC	1.15	0.84-1.57	0.38
Death-censored allograft survival
Black ethnicity	1.35	0.99-1.85	0.06
Diabetes	1.48	1.13-1.95	0.005	1.48	1.11-1.97	0.007
Time at ESKD	1.03	0.999-1.07	0.05
No alemtuzumab induction	1.34	0.96-1.87	0.09
Total HLA mismatch	1.10	1.00-1.21	0.043
Delayed graft function	2.01	1.54-2.64	< 0.001	1.80	1.37-2.38	< 0.001
CVC	0.74	0.56-0.96	0.023	0.74	0.57-0.97	0.028

Variables investigated; age, gender, ethnicity, cause of end-stage kidney disease (ESKD), time at ESKD, type of donor, allograft number, induction, diabetes, delayed graft function, total human leukocyte antigen mismatch, sensitization, in addition to type of hemodialysis access. Variables are reported in the table if considered potentially significant (P < 0.15). These variables were included in multivariable model, with only statistically significant variables (P < 0.05) reported on adjusted analysis. CI: Confidence interval; CVC: Central venous catheter; ESKD: End-stage kidney disease; HLA: Human leukocyte antigen; HR: Hazard ratio.